Table 4.
The therapeutic approach and post-therapy follow-up in the study groups.
| Patients with OSAS | OSAS-Treated Patients n = 50 |
PSG after Therapy | |||
|---|---|---|---|---|---|
| n = 87 | ENT | CPAP | BiPAP | n = 29 | |
|
n = 15 (17.2%) |
n = 3 (3.4%) |
n = 32 (36.8%) |
|||
| Neuromuscular disorders | 59 (67.8%) | ||||
| Spinal muscular atrophy (SMA) | 29 | 3 | - | 14 | 10 |
| Duchenne muscular dystrophy | 23 | 1 | - | 11 | 6 |
| Ulrich muscular dustrophy | 1 | - | - | 1 | 1 |
| Merosin deficient muscular dystrophy | 1 | - | - | 1 | 1 |
| Other myopathies | 5 | - | - | 3 | 2 |
| Skeletal disorders | 4 (4.6%) | ||||
| Achondroplasia (ACH) | 3 | 2 | 1 | - | 2 |
| Marfan syndrome | 1 | 1 | - | 1 | 1 |
| Complex abnormalities | 24 (27.5%) | ||||
| Craniosynostosis (Crouzon syndrome) | 2 | - | - | - | - |
| Prader–Willi syndrome (PWS) | 18 | 8 | 2 | 1 | 6 |
| Arnold–Chiari syndrome | 4 | - | - | - | - |